Cover ImageSALE
市場調查報告書

心臟衰竭治療藥的全球市場:2018年∼2022年

Global Heart Failure Drugs Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 599220
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
心臟衰竭治療藥的全球市場:2018年∼2022年 Global Heart Failure Drugs Market 2018-2022
出版日期: 2018年01月03日 內容資訊: 英文 113 Pages
簡介

關於心臟衰竭治療藥

全球心臟衰竭治療藥市場本質上是非專利的,因為許多仿製藥製造商和製藥巨頭正為疾病提供藥物。然而,EOM等創新藥物的到來有望改變市場動態。阿斯利康公司和諾華公司分別以其Toprol-XL和wog藥物佔了全球心力衰竭藥物市場的主要佔有率。這些公司也擁有強大的管道,預計在預測期間仍將保持市場領先地位。基於藥物類別,市場可以被分割成β受體阻滯劑,ARB和ACE抑製劑。血管緊張素II受體阻斷劑(ARB)是修飾腎素 - 血管緊張素系統的一組藥物。心臟病治療藥市場,由於降低心臟衰竭的死亡風險,控制心臟衰竭患者的住院的可能性到最小限度,ARB市場區隔成長。

Technavio的分析師預測,從2018年到在2222年之間,全球心臟衰竭藥治療市場將以10.46%的年複合成長率成長。

本報告提供全球心臟衰竭藥治療市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 簡介

  • 市場概要

第5章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第6章 市場規模

  • 市場定義
  • 市場規模:2017年
  • 市場規模及預測:2017-2022年

第7章 波特的五力分析

  • 買主談判力
  • 新加入廠商的威脅
  • 市場情形

第8章 市場區隔:各藥物等級

  • 市場區隔:各藥物等級
  • 比較:各藥物等級
  • β- 阻斷劑
  • ARB
  • ACE抑制劑(血管收縮素轉換酵素抑制劑)
  • 其他
  • 市場機會:各藥物等級

第9章 客戶形勢

第10章 地區形勢

  • 地理市場區隔
  • 地區比較
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 主要的已開發國家
  • 市場機會

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

  • 策略性聯盟的擴大
  • 發展中國家的投資的趨勢

第14章 業者情勢

  • 概要
  • 創造性破壞
  • 競爭情形

第15章 供應商分析

  • 交易廠商
  • 供應商的分類
  • 供應商的市場定位
  • Amgen
  • AstraZeneca
  • Bayer
  • Novartis

第16章 附錄

  • 簡稱清單
目錄
Product Code: IRTNTR20054

About Heart Failure Drugs

The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast period. Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors. Angiotensin II receptor blockers (ARB) are a group of pharmaceuticals that modify the renin-angiotensin system. The heart disease drugs market is experiencing growth in the ARBs segment because it reduces the risk of death caused by heart failure and minimizes the chance of hospitalization of people with heart failure.

Technavio's analysts forecast the global heart failure drugs market to grow at a CAGR of 10.46% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global heart failure drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of heart failure drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Heart Failure Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Amgen
  • AstraZeneca
  • Bayer
  • Novartis

Other Prominent Vendors

  • Gilead
  • GlaxoSmithKline
  • Pfizer
  • Teva Pharmaceutical industries

Market driver

  • Rising geriatric population
  • For a full, detailed list, view our report

Market trend

  • Investment inclination toward developing countries
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Threat of new entrants
  • Market condition

PART 08: MARKET SEGMENTATION BY DRUG CLASS

  • Segmentation by drug class
  • Comparison by drug class
  • Global beta blockers market
  • Global ARBs market
  • Global ACE inhibitors market
  • Global others market
  • Market opportunity by drug class

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Heart failure drugs market in Americas
  • Heart failure drugs market in EMEA
  • Heart failure drugs market in APAC
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Growing strategic alliances
  • Investment inclination toward developing countries

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive landscape

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen
  • AstraZeneca
  • Bayer
  • Novartis

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Heart function, before and after heart failure
  • Exhibit 02: Factors causing heart failure
  • Exhibit 03: Stages of heart failure
  • Exhibit 04: Major treatment options for various stages of heart failure
  • Exhibit 05: Global heart failure rate 2015
  • Exhibit 06: Parent market
  • Exhibit 07: Market characteristics
  • Exhibit 08: Market segments
  • Exhibit 09: Market definition: Inclusions and exclusions checklist
  • Exhibit 10: Market size 2017
  • Exhibit 11: Validation techniques employed for market sizing 2017
  • Exhibit 12: Global heart failure drugs market 2017-2022 ($ millions)
  • Exhibit 13: Global heart failure drugs market: Year-over-year growth 2018-2022 (%)
  • Exhibit 14: Five forces analysis 2017
  • Exhibit 15: Five forces analysis 2022
  • Exhibit 16: Bargaining power of buyers
  • Exhibit 17: Threat of new entrants
  • Exhibit 18: Market condition: Five forces 2017
  • Exhibit 19: Global heart failure drugs market by drug class 2017-2022 (%)
  • Exhibit 20: Comparison by drug class
  • Exhibit 21: Global beta blockers market 2017-2022 ($ millions)
  • Exhibit 22: Common beta blockers used for CVDs
  • Exhibit 23: Global beta blockers market: Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Global ARBs market 2017-2022 ($ millions)
  • Exhibit 25: Global ARBs market: Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Global ACE inhibitors market 2017-2022 ($ millions)
  • Exhibit 27: Adverse effects of ACE inhibitors
  • Exhibit 28: Global ACE inhibitors market: Year-over-year growth 2018-2022 (%)
  • Exhibit 29: Global others market 2017-2022 ($ millions)
  • Exhibit 30: Global others market: Year-over-year growth 2018-2022 (%)
  • Exhibit 31: Market opportunity by drug class
  • Exhibit 32: Customer landscape
  • Exhibit 33: Global heart failure drugs market by geography 2017-2022 (%)
  • Exhibit 34: Regional comparison
  • Exhibit 35: Heart failure drugs market in Americas 2017-2022 ($ millions)
  • Exhibit 36: Heart failure drugs market in Americas: Year-over-year growth 2018-2022 (%)
  • Exhibit 37: Heart failure drugs market in EMEA 2017-2022 ($ millions)
  • Exhibit 38: Heart failure drugs market in EMEA: Year-over-year growth 2018-2022 (%)
  • Exhibit 39: Heart failure drugs market in APAC 2017-2022 ($ millions)
  • Exhibit 40: Top Asian countries in terms of population with diabetes
  • Exhibit 41: Heart failure drugs market in APAC: Year-over-year growth 2018-2022 (%)
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: World population by age group 2015-2050 (millions)
  • Exhibit 45: Percentage of population aged 65 and above by region 2015 and 2050
  • Exhibit 46: Major complications of diabetes
  • Exhibit 47: Global obesity facts 2014
  • Exhibit 48: Percentage of workday spent walking or standing versus sitting in selected occupation 2016
  • Exhibit 49: Side effects of the drugs used in heart failure treatment and management
  • Exhibit 50: Demographic and economic snapshot of India and China
  • Exhibit 51: Vendor landscape
  • Exhibit 52: Landscape disruption
  • Exhibit 53: Competitive structure analysis of global heart failure drugs market
  • Exhibit 54: Vendors covered
  • Exhibit 55: Vendor classification
  • Exhibit 56: Market positioning of vendors
  • Exhibit 57: Amgen: Vendor overview
  • Exhibit 58: Amgen: Business segments
  • Exhibit 59: Amgen: Organizational developments
  • Exhibit 60: Amgen: Geographic focus
  • Exhibit 61: Amgen: Segment focus
  • Exhibit 62: Amgen: Key offerings
  • Exhibit 63: AstraZeneca: Vendor overview
  • Exhibit 64: AstraZeneca: Business segments
  • Exhibit 65: AstraZeneca: Organizational developments
  • Exhibit 66: AstraZeneca: Geographic focus
  • Exhibit 67: AstraZeneca: Segment focus
  • Exhibit 68: AstraZeneca: Key offerings
  • Exhibit 69: Bayer: Vendor overview
  • Exhibit 70: Bayer: Business segments
  • Exhibit 71: Bayer: Organizational developments
  • Exhibit 72: Bayer: Geographic focus
  • Exhibit 73: Bayer: Segment focus
  • Exhibit 74: Bayer: Key offerings
  • Exhibit 75: Novartis: Vendor overview
  • Exhibit 76: Novartis: Business segments
  • Exhibit 77: Novartis: Organizational developments
  • Exhibit 78: Novartis: Geographic focus
  • Exhibit 79: Novartis: Segment focu
  • Exhibit 80: Novartis: Key offerings
Back to Top